04/01/2026
Starting estrogen earlier in perimenopause may significantly reduce the risk of breast cancer, heart attack, and stroke. Let that sit for a moment.
For decades, women were told that hormone therapy caused breast cancer and heart disease. That message, rooted largely in one flawed and widely misinterpreted study, created fear that led countless women to suffer unnecessarily.
What newer research continues to reinforce is something many clinicians have long understood: timing matters.
When estrogen is introduced during perimenopause or early menopause, at the point when the body is first losing its natural hormonal protection, it may help protect against breast cancer, cardiovascular disease, stroke, cognitive decline, osteoporosis, and metabolic disease.
There is an important distinction here. Hormone therapy started within the early window of hormonal decline appears to have very different effects than therapy started a decade or more after menopause, when underlying damage has already accumulated.
This is why the advice to simply wait it out can be harmful.
Each year spent in perimenopause without support may contribute to faster bone loss, rising cardiovascular risk, worsening metabolic health, and changes in brain function.
Estrogen is not about vanity or symptom suppression alone. It plays a foundational role in protecting long-term health across multiple systems in the body.
Starting support earlier, when symptoms first appear, may be one of the most impactful health decisions a woman makes for her future.
This does not mean hormone therapy is right for everyone. But it does mean every woman deserves an informed, individualized conversation with a provider who understands the current evidence.
If you are symptomatic in perimenopause, you are not too young to ask about hormone therapy. You may actually be in the optimal window.
And no one should be told to suffer in silence.
